|2.||Wounds and Injuries (Trauma)
|3.||Spinal Cord Injuries (Spinal Cord Injury)
|1.||Kaplan, Frederick S: 15 articles (12/2012 - 01/2002)|
|2.||Shore, Eileen M: 15 articles (12/2012 - 01/2002)|
|3.||Potter, Benjamin K: 10 articles (09/2015 - 01/2006)|
|4.||Forsberg, Jonathan A: 7 articles (09/2015 - 04/2014)|
|5.||Pignolo, Robert J: 7 articles (12/2012 - 02/2007)|
|6.||Levi, Benjamin: 6 articles (12/2015 - 09/2014)|
|7.||Glaser, David L: 6 articles (09/2009 - 09/2003)|
|8.||Agarwal, Shailesh: 5 articles (12/2015 - 09/2014)|
|9.||Davis, Thomas A: 5 articles (09/2015 - 09/2014)|
|10.||Wu, Ching-Lan: 5 articles (05/2015 - 02/2012)|
|1.||Indomethacin (Indometacin)FDA LinkGeneric
12/01/2006 - "We were unable to demonstrate a statistically significant reduction in the incidence of severe heterotopic ossification with the use of indometacin when compared with a placebo (p = 0.722). "
01/01/1994 - "Statistical analysis revealed that indomethacin was effective in decreasing the overall incidence of heterotopic ossification (p < 0.01). "
01/01/1992 - "Irradiation and indomethacin were effective in the prevention of severe heterotopic ossification. "
02/01/2009 - "Although the quality of the available studies made a proper meta-analysis inappropriate, the incidence of heterotopic ossification was significantly lower in patients treated with radiation than in patients receiving indomethacin (five of 160 versus 20 of 224, respectively). "
02/01/2007 - "Selective COX-2 inhibitor versus indomethacin for the prevention of heterotopic ossification after hip replacement: a double-blind randomized trial of 100 patients with 1-year follow-up."
04/01/2013 - "In this study, we investigated whether etoricoxib, a selective cyclo-oxygenase-2 (COX-2) inhibitor that produces fewer gastrointestinal side effects, is an effective alternative for the prevention of heterotopic ossification. "
04/01/2013 - "No heterotopic ossification was found in 62 % of the patients that took etoricoxib; 31 % of the patients had Brooker grade 1 and 7 % Brooker grade 2 ossification. "
08/01/2013 - "Response to comment on Brunnekreef et al.: Is etoricoxib effective in preventing heterotopic ossification after primary total hip arthroplasty?"
08/01/2013 - "Comment on Brunnekreef et al.: Is etoricoxib effective in preventing heterotopic ossification after primary total hip arthroplasty?"
04/01/2013 - "Etoricoxib seems effective in preventing heterotopic ossification after total hip arthroplasty. "
|3.||meloxicam (Mobic)FDA LinkGeneric
01/01/2009 - "The clinical relevance of this study is that meloxicam and parecoxib may be helpful in reducing heterotopic ossification in humans."
12/01/2002 - "Prophylaxis of heterotopic ossification after total hip arthroplasty: a prospective randomized study comparing indomethacin and meloxicam."
06/01/2004 - "We were not able to show any difference between Indomethacin and Meloxicam in preventing heterotopic ossification after primary hip arthroplasty. "
04/01/2003 - "Indomethacin versus meloxicam for prevention of heterotopic ossification after total hip arthroplasty."
12/01/2002 - "We performed a randomized, prospective study on the prophylaxis of heterotopic ossification (HO) after total hip arthroplasty (THR), comparing indomethacin and the selective COX-2 inhibitor meloxicam. "
|4.||Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA
01/01/2008 - "The efficacy of NSAIDs in the avoidance of heterotopic ossification has been documented in controlled clinical trials, but the inherent risks (e.g. "
10/01/2015 - "Locally delivered NSAIDs may be useful for heterotopic ossification prophylaxis due to effects on osteoblast viability and lack of negative effects on wound healing. "
10/01/2014 - "Non-steroidal anti-inflammatory drugs (NSAIDs) are administered as prophylaxis of heterotopic ossification for 10 days. "
06/01/2014 - "Heterotopic ossification was more likely to develop in patients undergoing acetabuloplasty along with osteochondroplasty and in those who did not receive prophylactic postoperative NSAIDs. "
12/01/2010 - "open hip surgery is known to be a risk for heterotopic ossification (HO), and nonsteroidal anti-inflammatory drugs (NSAIDs) have been widely recognized as an effective prevention. "
|5.||Etidronic Acid (HEDP)FDA LinkGeneric
12/01/1994 - "Etidronic acid in higher dosages (10 to 20 mg/kg/day orally) is effective in reducing the incidence of heterotopic ossification and its ensuing complications in both neurological and post-surgical patients. "
12/01/1995 - "In the control group, heterotopic ossification was found in 10 patients (20%) during the period, while in the EHDP group, it was found in one patient (3.7%) during the treatment period after the operation. "
12/01/1995 - "We investigated the status of the development of heterotopic ossification and compared the frequency of heterotopic ossification in the EHDP group with that in the untreated (control) group to evaluate the efficacy and safety of EHDP. "
05/01/1991 - "Resection of heterotopic ossification can be successful using disodium etidronate to decrease the risk of recurrence, and resection can improve range of motion and nerve function. "
01/01/1987 - "Resection of heterotopic ossification and Didronel therapy--regaining wheelchair independence in the spinal cord injured patient."
|6.||Naproxen (Naprosyn)FDA LinkGeneric
12/16/2015 - "Effect of Naproxen Prophylaxis on Heterotopic Ossification Following Hip Arthroscopy: A Double-Blind Randomized Placebo-Controlled Trial."
12/16/2015 - "Beckmann, MD, MS, et al.: "Effect of Naproxen Prophylaxis on Heterotopic Ossification Following Hip Arthroscopy: A Double-Blind Randomized Placebo-Controlled Trial"."
02/19/1996 - "One year after the operation 4/27 in the naproxen-treated group and 12/23 in the control group had heterotopic ossification (p < 0.05). "
02/19/1996 - "Three months after the operation 12/23 patients in the control group and 3/27 in the naproxen-treated group had developed heterotopic ossification. "
02/19/1996 - "[Eight days of naproxen therapy can prevent heterotopic ossification after total hip alloplasty]."
|7.||celecoxib (Celebrex)FDA Link
11/01/2015 - "The efficacy of celecoxib in preventing heterotopic ossification recurrence after open arthrolysis for post-traumatic elbow stiffness in adults."
03/01/2014 - "Celecoxib at a dose of 10 mg/(kg x d) can effectively reduce the incidence of heterotopic ossification in rats."
02/01/2013 - "However, the effects of celecoxib on heterotopic ossification at other locations remain unclear. "
06/01/2012 - "Multivariate analysis showed that celecoxib prophylaxis was the single most important variable when predicting the occurrence of heterotopic ossification. "
06/01/2012 - "The overall incidence of heterotopic ossification in the celecoxib-treated patients was 23% (no cases of Brooker grade 3 or 4 ossifications), compared to 55% in the untreated patients (Brooker grade 3 and 4: 8.9%). "
|8.||rofecoxib (Vioxx)FDA Link
09/01/2007 - "A prospective two-stage study design for phase 2 clinical trials with 42 patients was used to determine if rofecoxib (a COX-2 inhibitor) 50 mg oral for 7 days prevents heterotopic ossification. "
02/01/2007 - "After short-term administration, the selective COX-2 inhibitor rofecoxib was effective in preventing heterotopic ossification after total hip arthroplasty."
09/01/2007 - "Using a two-stage study design for phase 2 clinical trials, a 7-day treatment of a COX-2 inhibitor (rofecoxib) prevents effectively the formation of heterotopic ossification after cemented primary total hip arthroplasty."
09/01/2007 - "Rofecoxib inhibits heterotopic ossification after total hip arthroplasty."
12/01/2004 - "Prevention of heterotopic ossification after spinal cord injury with COX-2 selective inhibitor (rofecoxib)."
10/01/2005 - "Amino-bisphosphonates in heterotopic ossification: first experience in five consecutive cases."
04/01/1983 - "The effect of diphosphonates on heterotopic ossification in regenerating Achilles tendon of the mouse."
03/27/1982 - "Diphosphonates for heterotopic ossification."
01/01/1989 - "Bisphosphonates are used in man to inhibit ectopic calcification, including dental tartar and ectopic ossification. "
04/01/2005 - "The bisphosphonates reduce bone turnover, increase bone mass, and decrease fracture risk and therefore have a significant place in the management of skeletal disorders including osteoporosis, Paget's disease, bone metastases, osteogenesis imperfecta, and heterotopic ossification."
|10.||Diclofenac (SR 38)FDA LinkGeneric
01/01/1998 - "Prevention of periarticular heterotopic ossification after endoprosthetic hip joint replacement by means of diclofenac."
01/01/1992 - "We recommend Diclofenac prophylaxis against heterotopic ossification after hip operations in view of the serious clinical effects of this complication and its quoted incidence of 15% to 80%."
01/01/1992 - "In a double-blind prospective randomised study we examined the effects of Diclofenac on heterotopic ossification after hip arthroplasty. "
09/01/1998 - "Irradiation within 16-20 h before operation and use of NSAID (Voltaren resinat) can reduce the incidence of clinically relevant heterotopic ossification after total hip replacement."
02/01/2004 - "In a monocentric, randomized, placebo-controlled double-blind study, we investigated the efficacy of two doses of diclofenac-cholestyramine for the prevention of heterotopic ossification (HO). "
12/01/1986 - "It was demonstrated that treatment with 2,000 rads of radiation that was initiated within four days after the total hip arthroplasty was highly effective in the prevention of heterotopic ossification and in the prevention of recurrence after resection of existing ossification. "
06/01/2012 - "In spite of the proven efficacy of pharmacological prophylaxis of heterotopic ossification following total hip arthroplasty, its routine use is still debated, and no data are available regarding the adherence to its administration in clinical practice. "
09/01/2003 - "As a result of this pilot study, 500 cGy radiation treatment appears to be effective in the prevention of clinically significant heterotopic ossification after total hip arthroplasty."
12/01/1986 - "In a previous prospective study, patients who were at high risk for heterotopic ossification after total hip arthroplasty were identified and an effective regimen for its prevention was established. "
12/01/1986 - "A prospective study was done to evaluate the efficacy of treatment with 1,000 rads of radiation in the prevention of heterotopic ossification after total hip arthroplasty in patients who are at high risk. "
08/01/1997 - "Since 1987, two prospectively randomized trials were performed in patients with high-risk factors to develop heterotopic ossification: the first (HOP 1) to assess the prophylactic efficacy of postoperative low vs. medium dose radiotherapy, and the second (HOP 2) to assess the prophylactic efficacy of pre vs. postoperative radiotherapy. "
08/30/1994 - "In June 1992 a prospectively randomized trial was initiated to assess the comparative efficacy of pre- vs. postoperative prophylactic radiotherapy in patients with high risk to develop heterotopic ossification after hip surgery. "
10/01/1996 - "The data about the high therapeutic efficacy of postoperative radiotherapy for prevention of heterotopic ossification were confirmed. "
10/01/2014 - "Radiotherapy (RT) is effective in preventing heterotopic ossification (HO) around acetabular fractures requiring surgical reconstruction. "
07/01/2015 - "Radiotherapy for the prophylaxis of heterotopic ossification: A systematic review and meta-analysis of randomized controlled trials."
|3.||Hip Replacement Arthroplasty (Total Hip Replacement)
12/01/1997 - "Two prospective trials were undertaken to assess the comparative efficacy of early postoperative irradiation with different radiation doses versus the postoperative use of nonsteroidal antiinflammatory drugs (NSAID) for prevention of heterotopic ossification (HO) following prothetic total hip replacement (THP). "
12/01/1997 - "A randomized trial was undertaken to assess the comparative efficacy of early postoperative irradiation with either 5 or 7 Gy vs. the use of nonsteroidal antiinflammatory drug (NSAID) for prevention of heterotopic ossification (HO) following prosthetic total hip replacement (THP). "
01/01/2009 - "The ability of various pre- or peri-operative variables to determine the risk of developing moderate to severe heterotopic ossification (HO) six to twelve months after surgery was investigated among 407 patients undergoing elective total hip replacement (THR) surgery and allocated to placebo in a randomised controlled trial evaluating NSA IDs-based prophylaxis for HO. "
10/01/2001 - "This study prospectively evaluated 928 patients with 1318 primary total hip replacements for heterotopic ossification (HO). "
04/01/2000 - "This study evaluates 706 patients with 835 primary total hip replacements documented in a prospective fashion in a multicenter study with respect to correlation between heterotopic ossification (HO) and clinical outcome. "
09/01/2015 - "The present report details the management of severe, treatment-resistant PLP in a 72-year-old man with a traumatic left transradial amputation and a comorbid complication of heterotopic ossification (HO). "
09/01/2015 - "Heterotopic ossification (HO) is common after combat-related amputations and surgical excision remains the only definitive treatment for persistently symptomatic HO. "
09/01/2015 - "What Risk Factors Predict Recurrence of Heterotopic Ossification After Excision in Combat-related Amputations?"
09/01/2015 - "Heterotopic ossification (HO) develops in a majority of combat-related amputations wherein early bacterial colonization has been considered a potential early risk factor. "
08/01/2015 - "Heterotopic ossification (HO) develops after nearly 2/3 of traumatic blast amputations in the contemporary battlefield. "
|5.||Spinal Fusion (Spondylosyndesis)
05/01/2010 - "While the occurrence of heterotopic ossification has previously been reported when rhBMP-2 has been used for spinal fusion surgery, this case demonstrates that it can occur to a much greater degree than previously seen."
03/01/1992 - "Heterotopic ossification developed around the hip in all cases--two after bilateral adductor releases at the operative site and the third after spinal fusion at a site unrelated to the surgery."
05/01/2010 - "Recombinant human bone morphogenetic protein 2-induced heterotopic ossification of the retroperitoneum, psoas muscle, pelvis and abdominal wall following lumbar spinal fusion."
08/01/2013 - "The aim of this study was to evaluate the efficacy of low-dose recombinant human bone morphogenetic protein-2 (rhBMP-2) delivered with a heparin based polylectrolyte complex (PEC) carrier in facilitating posterior spinal fusion while concurrently minimizing seroma and heterotopic ossification. "